| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/09/2003 | WO2002080901A3 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates |
| 01/09/2003 | WO2002069887A3 Virucidal compositions |
| 01/09/2003 | WO2002062777A9 Amino ceramide-like compounds and therapeutic methods of use |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002059102A3 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 01/09/2003 | WO2002058725A3 Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine |
| 01/09/2003 | WO2002046423A3 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002043756A3 Method for obtaining antigenic aggregates and the use thereof in formulations |
| 01/09/2003 | WO2002043664A3 Reducing cellular damage in the human body |
| 01/09/2003 | WO2002038769A3 Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2 |
| 01/09/2003 | WO2002036625A3 Prokineticin polypeptides, related compositions and methods |
| 01/09/2003 | WO2002032943A3 Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
| 01/09/2003 | WO2002020041A3 Eia vaccine and diagnostic |
| 01/09/2003 | WO2002013855A3 Vaccines containing ribavirin and methods of use thereof |
| 01/09/2003 | WO2002008251A3 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/09/2003 | WO2002005850A3 Enhancement of the action of anti-infective agents |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001081376A3 Apo-ai/aii peptide derivatives |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001070776A3 Nimr compositions and their methods of use |
| 01/09/2003 | WO2001070213A3 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001009609A3 Hepatitis c viral antigen immunoassay detection systems |
| 01/09/2003 | US20030009032 For inhibiting the replication or infectivity of a virus; therapy |
| 01/09/2003 | US20030009010 As vaccines for therapy and prophylaxis of Haemophilus influenzae infection |
| 01/09/2003 | US20030008924 Providing cell which overexpresses a Bcl-2 family protein; gossypol compound; treating with cell with an effective amount of gossypol compound under conditions such that apoptosis in cell is modulated |
| 01/09/2003 | US20030008917 For preparation of disinfectants, sterilizing formulations, antiseptics, preservatives, which are suitable for the sterilization and disinfection of surfaces and surgical instruments, and preservation of cosmetics, foods |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008905 Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008899 For use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex |
| 01/09/2003 | US20030008894 Antimicrobial quinolones, their compositions and uses |
| 01/09/2003 | US20030008887 Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 01/09/2003 | US20030008882 Proteomimetic compounds and methods |
| 01/09/2003 | US20030008877 CCR5 antagonists useful for treating AIDS |
| 01/09/2003 | US20030008856 Treatment of septic shock |
| 01/09/2003 | US20030008841 Anti-HCV nucleoside derivatives |
| 01/09/2003 | US20030008840 Methods for treating cancer |
| 01/09/2003 | US20030008827 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008399 Controlling viral replication or gene expression in a cell; obtain cell infected with virus, transform with nucleotide sequence expressng preferential replicases, monitor viral gene expression |
| 01/09/2003 | US20030008398 Nucleotide sequences coding polypeptide for use in the treatment of autoimmune and inflammatory diseases |
| 01/09/2003 | US20030008391 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008390 Genetically engineered cell for use in the generation of viral vector for use in gene therapy |
| 01/09/2003 | US20030008376 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008349 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008279 Cells for use in the diagnosis and treatment of viral diseases |
| 01/09/2003 | US20030008274 Nucleotide sequences coding polypeptide for use in the treatment of and prevention of viral diseases |
| 01/09/2003 | US20030008023 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008018 Acrochordon alleviation |
| 01/09/2003 | US20030008012 Bactericide in solid form |
| 01/09/2003 | US20030008008 Fast dissolving orally consumable films |
| 01/09/2003 | US20030007983 Two-hybrid assay that detects HIV-1 reverse transcriptase dimerization |
| 01/09/2003 | US20030007980 Urease-based vaccine and treatment for helicobacter infection |
| 01/09/2003 | US20030007979 Intranasal administering |
| 01/09/2003 | US20030007977 Vaccine containing amino acid |
| 01/09/2003 | US20030007976 Anticancer agents; sensitivity to Mycobacterium |
| 01/09/2003 | US20030007958 Mixture of silica, flow control agent and carrier; cyclooxygenase inhibitor, antiinflammatory agents |
| 01/09/2003 | US20030007934 Delivery of stimulants through an inhalation route |
| 01/09/2003 | US20030007933 Delivery of muscle relaxants through an inhalation route |
| 01/09/2003 | US20030005924 Delivery of beta-blockers through an inhalation route |
| 01/09/2003 | CA2452364A1 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452082A1 Extracellular messengers |
| 01/09/2003 | CA2451840A1 Fused pyrimidine dhfr inhibitors as antibacterials |
| 01/09/2003 | CA2451816A1 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 01/09/2003 | CA2451800A1 Fused pyrimidines as d-alanyl-d-alanine ligase inhibitors |
| 01/09/2003 | CA2451795A1 Cell-based high-throughput screening methods |
| 01/09/2003 | CA2451755A1 Pyridazinone |
| 01/09/2003 | CA2451739A1 Hcv e1e2 vaccine compositions |
| 01/09/2003 | CA2451236A1 Peptides for use as translocation factors |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2450982A1 New derivatives of oxazolidinones as antibacterial agents |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/08/2003 | EP1273592A2 Process for the purification of pharmacologically active proteins through cationic exchange chromatography |
| 01/08/2003 | EP1273587A1 Process for the preparation of a 3-vinylcephem compound |
| 01/08/2003 | EP1273586A1 Penicillin crystal and process for producing the same |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273571A1 Nitrogenous compounds and antiviral drugs containing the same |
| 01/08/2003 | EP1273298A2 Ritonavir in combination with an additional HIV protease inhibitor for treating aids |
| 01/08/2003 | EP1273297A1 Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction) |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1272652A2 Herpes viruses for immune modulation |
| 01/08/2003 | EP1272633A2 Compositions and methods for dendritic cell-based immunotherapy |
| 01/08/2003 | EP1272610A1 Mutant bank |
| 01/08/2003 | EP1272527A2 Anti-d monoclonal antibodies |
| 01/08/2003 | EP1272526A1 Enhancement of antibody-mediated immune responses |
| 01/08/2003 | EP1272515A2 Immunoregulator |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272512A2 Immunokine composition and method |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |